Epilepsy, as a common chronic disease of the nervous system, is characterized by recurrent, paroxysmal, and transient disturbances in cerebral function resulting from aberrant neuronal hyperactivity within the brain [1]. Children represent one of the two peak populations for epilepsy [2]. Management of pediatric epilepsies poses unique challenges regarding diagnosis, treatment options, comorbidities, and the potential for these factors to interact with processes in the developing brain [3]. Anti-seizure medications (ASMs) are a primary treatment for epilepsy, with over 20 drugs having been approved [4].
22
SEP
SEP
0